Orphazyme upgrades after careful spending year

Several reporting parameters have been adjusted upward by biotech firm Orphazyme, which has fared better than feared in 2021.
Photo: Orphazyme/PR
Photo: Orphazyme/PR
by marketwire, translated by daniel pedersen

Orphazyme tightened its belt in 2021, resulting in lower-than-expected costs for the year. Now, the biotech company is upgrading its 2021 financial forecast a few months prior to the report's full release, a press release announced on Tuesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading